|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Therefore, inhibition of the RET kinase is a promising targeted therapy for cancer patients whose tumors harbor a RET rearrangement.
|
30210625 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results provide proof-of-concept of the clinical actionability of RET alterations, and identify selective RET inhibition by LOXO-292 as a promising treatment in heavily pretreated, multikinase inhibitor-experienced patients with diverse RET-altered tumors.
|
29912274 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Next-generation sequencing analysis detected a NCOA4-RET fusion transcript joining exon 7 or 8 of NCOA4 gene and exon 12 of RET gene in 6 cases of intercalated duct type IC; and a novel TRIM27-RET fusion transcript between exons 3 and 12 in 2 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of apocrine IC.
|
30045065 |
2018 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
And Chromatin Immunoprecipitation assay confirms that the derepressed tumor suppressor genes belong to BMI-1 targets and the enrichment levels of H2AK119ub1 at their promoters is decreased upon PTC-209 treatment.
|
29886801 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These results implicate EGFR as a key regulator of RET activation in A+AD and suggest that EGFR inhibitors may be therapeutic in patients with A+AD tumors even in the absence of an EGFR or RET mutation.
|
28460442 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Using chemical genomics in conjunction with phosphoproteomic analyses in <i>RET</i>-rearranged cells, we identify the CCDC6-RET<sup>I788N</sup> mutation and drug-induced mitogen-activated protein kinase pathway reactivation as possible mechanisms by which tumors may escape the activity of RET inhibitors.
|
28615362 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Multiple endocrine neoplasia type 2A (MEN2A) is a condition with inherited autosomal dominant mutations in RET (rearranged during transfection) gene that predisposes the carrier to extremely high risk of medullary thyroid cancer (MTC) and other MEN2A-associated tumors such as parathyroid cancer and/or pheochromocytoma.
|
28099363 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Eight patients had an early disseminated manifestation, seven with KIF5B-RET rearranged tumor.
|
28082048 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In an exploratory assessment of OS, progression-free survival, and objective response rate, cabozantinib appeared to have a larger treatment effect in patients with RET M918T mutation-positive tumors compared with patients not harboring this mutation.
|
29045520 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Together, our data show that RET expression promotes a more mesenchymal phenotype with reduced cell-cell adhesion and increased invasiveness in PTC cell models, but is more important for tumour cell survival, proliferation and anoikis resistance in MTC models.
|
27872141 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Vandetanib, an oral multi-TKI that targets RET in particular, was initiated, and a rapid reversal of the hypercortisolism was observed without any change in tumor size.
|
28068878 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Hyper-methylated CpG loci included the known the tumor suppressor gene RET (p = 5.72 x 10-10), as well as loci in differentially methylated regions for GSG1L, MIR4493, NTNG1, MCIDAS, ZNF568, and RERG.
|
28257124 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We found a significant association between the localization of RET mutations and the expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid cancer).
|
28181547 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Our results show that PTC presented different patterns of PN immunoreaction, stromal PN being significantly associated with advanced tumor stage and extrathyroidal extension.
|
29435461 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The pattern of tumors in this patient is unusual for either one of the APC- orRASAL1-associated neoplasms and her non-MEN 2-associated MTC contained a RET variant like other sporadic MTCs.
|
29518763 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i>, knockdown of RET inhibits tumor growth.
|
28490466 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
ATF4 was identified as a negative regulator of RET, a candidate tumor suppressor gene, and may be a molecular marker that distinguishes patients at high risk of MTC from those with a longer survival prognosis.
|
27935748 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Previously, it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the MET-addicted glioblastoma model E98, yet did not prevent development of recurrent and cabozantinib-resistant tumors.
|
28751462 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The multifocality rate of PTC was 35.1% and mPTC were shown to have larger primary tumor diameter, higher rate of lymph node metastasis and less number of accompanying non-cancerous lesions than single PTC in one or both gender groups.
|
28315434 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Patients had a confirmed sporadic MTC diagnosis, a serum calcitonin measurement >100 pg/mL, and tumor tissue biopsy results providing RET M918T mutation status.
|
28911154 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In the present study, we also showed that the systemic administration of a water soluble NSC311153 analog in a mouse MTC xenograft model inhibited the tumor growth through RET downregulation.
|
28498409 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
BRAF<sup>V600E</sup> was associated with older age and larger tumor size (p < 0.05), and RET/PTC3 was associated with a larger tumor size and multifocality (p < 0.05).
|
27849443 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Importantly, in vivo PTC-209 administration significantly reduced tumor growth in a HNSCC xenograft model probably by Bmi1 inhibition and impaired cell proliferation.
|
29200967 |
2017 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
|
26935956 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Overall, our findings indicate that NDI-dependent RET G4 stabilization represents a suitable approach to control RET transcription and delineate the rationale for the development of G4 stabilizing-based treatments for MTC as well as for other tumors in which RET may have functional and therapeutic implications.
|
27351133 |
2016 |